ArticleInternational urology and nephrology2026
Adjustable dual-balloon therapy: quality of life after prostate incontinence treatment.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modifications of Anti-Incontinence Procedures for Radiated Patients: A Narrative Review.Current urology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the quality of life (QoL) and surgical outcomes of adjustable dual-balloon continence therapy (DBACT), ProACT™ is a minimally invasive treatment for post-prostatectomy urinary incontinence.
methodsIn this retrospective, single-surgeon review conducted between September 2020 and March 2023, 21 patients with moderate-to-severe post-prostatectomy incontinence underwent ProACT™ placement at a Midwest academic center. A chart review was conducted to extract procedural and outcomes data. Postoperative QoL surveys, including pads-per-day (PPD) and incontinence QoL (IQoL) scores, were administered.
resultsThe average patient age was 70 years. Six (28.6%) of the 21 patients had prior radiation. The average operating time was 61.14 min. Patients needed an average of 3.33 adjustments post-surgery. The average decrease in PPD was 5.93, with 81% of patients achieving meaningful dryness with the use of ≤ 2 PPD. 76% of patients felt that ProACT™ helped their incontinence, improved their QoL, was worthwhile, and would recommend it to others. Of the 15 non-radiated patients, one had complications (6.67%). Of the 6 radiated patients, 5 (83.3%) had complications. There were no erosions in patients who were not previously radiated. There were no serious complications requiring prolonged hospitalization, such as sepsis or fistula formation.
conclusionsProACT™ is a safe and effective treatment for incontinence after prostatectomy with high patient satisfaction and a low complication rate in patients without prior radiation. For radiated patients, ProACT™ can be efficacious, but they should be counseled about slower improvement times and higher complication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.